Lung cancer trial uses DNA traces to guide Post-Surgery immunotherapy

NCT ID NCT07120698

Recruiting now Disease control Sponsor: Guangdong Association of Clinical Trials Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated May 15, 2026 · Updated 21 times

Summary

This study is for people with stage II-IIIB non-small cell lung cancer who had surgery after initial chemotherapy and immunotherapy but still had some cancer cells left. Researchers want to see if using a sensitive blood test (MRD) to guide additional treatment with the immunotherapy drug sintilimab can help prevent the cancer from coming back. About 115 participants will receive sintilimab based on their MRD results, and the study will track how long they stay cancer-free.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Guangdong Provincial People's Hospital
RECRUITING

Guangzhou, Guangdong, 510080, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
The third people's hospital of chengdu
RECRUITING

Chengdu, Sichuan, 610031, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ADJUVANT IMMUNOTHERAPY II-IIIB STAGES II-IIIB STAGES MRD NSCLC (NON-SMALL CELL LUNG CANCER)